Novel oral anticoagulants

Novel oral anticoagulants has been studied in 8 papers since 2016: 4 observational studies in people, 3 reviews; 4 in the past year. The newest story, Oct 26, 2026: “Newer blood thinners linked to lower cataract risk”.

Intervention

8 papers study it13 findingsUpdated

2 new papers in 30 daysSee all 8 papers on novel oral anticoagulants

At a glance

Independent labs found the same change in people. 5 independent labs in 7 countries.

“NOAC use was associated with a significantly lower risk of cataract compared with warfarin (HR 0.89, 95% CI 0.87–0.92).”
Non-vitamin K antagonist oral anticoagulants versus warfarin and the risk of cataract in patients with atrial fibrillation: A real-world cohort studyESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4081

2 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 5 independent labs in 7 countries
  • 2 findings against
  • Humans4
  • In silico1

What did studies of novel oral anticoagulants find?

9

Studies of novel oral anticoagulants measured 9 outcomes, among them stroke, hemorrhagic stroke and major bleeding.

Stroke

downin humans1no changein humans1

2 studies
  1. Novel oral anticoagulants were not clearly linked with stroke in humans (atrial fibrillation, post-discharge octogenarian patients, vs VKA) (P > 0.05).

    “The risk of stroke or major bleeding was not different either (all P > 0.05).”

    Humansatrial fibrillation, post-discharge octogenarian patients, vs VKAmedian of 2.6-yearsn = 330

    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation

    Journal of thrombosis and thrombolysis

  2. Novel oral anticoagulants prevent stroke in humans (atrial fibrillation with frailty).

    “Low-dose NOACs reduced stroke in frail octogenarians but bleeding risk persisted.”

    Reviewatrial fibrillation with frailtylow-doselow-dose

    Frailty and advanced age in atrial fibrillation: Implications for treatment strategies and clinical outcomes - A systematic review

    Indian heart journal

More on Stroke

Hemorrhagic stroke

no changein humans1

1 study
  1. Novel oral anticoagulants were not clearly linked with hemorrhagic stroke in humans (End-stage renal failure and atrial fibrillation; compared with aspirin).

    “There was no ischemic stroke event among NOAC users, who did not have significantly different risk of hemorrhagic stroke compared to aspirin users.”

    HumansEnd-stage renal failure and atrial fibrillation; compared with aspirin

    Safety and Effectiveness of Antithrombotics in Patients with End-Stage Renal Failure and Atrial Fibrillation: A Population-Based Study with Competing Risk Analysis

    AHA Scientific Sessions 2026 abstract

More on Hemorrhagic stroke

Major bleeding

no changein humans1

1 study
  1. Novel oral anticoagulants were not clearly linked with major bleeding in humans (atrial fibrillation, post-discharge octogenarian patients, vs VKA) (P > 0.05).

    “No differences in stroke and major bleeding events among these treatment groups were revealed.”

    Humansatrial fibrillation, post-discharge octogenarian patients, vs VKAmedian of 2.6-yearsn = 330

    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation

    Journal of thrombosis and thrombolysis

Mortality

no changein humans1HR 0.72

1 study
  1. Novel oral anticoagulants were not clearly linked with mortality in humans (HR 0.72, 95% CI 0.50-1.03, P = 0.07).

    “The adjusted risk of all-cause death was not different in the NOAC group, compared with the VKA group (hazard ratio [HR], 0.72; 95% confidence intervals [CI] 0.50-1.03; P = 0.07).”

    Humansatrial fibrillation, post-discharge octogenarian patients, multivariable Cox regression vs VKAmedian of 2.6-yearsn = 330

    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation

    Journal of thrombosis and thrombolysis

Excess bleeding

downin humans1

1 study
  1. Novel oral anticoagulants decrease excess bleeding in humans (Compared with vitamin K antagonists).

    “Excess bleedings were lower with NOACs in comparison to VKAs, but bleeding patterns were disparate among them”

    ReviewCompared with vitamin K antagonists

    Efficacy and safety of novel anticoagulants in the elderly

    Journal of geriatric cardiology : JGC

Thrombotic events

downin humans1

1 study
  1. Novel oral anticoagulants prevent thrombotic events in humans (Equal or greater efficacy).

    “the benefit of NOACs is consistent among all age groups, featuring equal or greater efficacy in preventing thrombotic events.”

    Review

    Efficacy and safety of novel anticoagulants in the elderly

    Journal of geriatric cardiology : JGC

Cost-effectiveness

downin silico1

1 study
  1. Novel oral anticoagulants decrease cost-effectiveness in silico (Atrial fibrillation; excluding apixaban).

    “In elderly aged ≥75years, cost effectiveness of NOACs (except apixaban) decreased, owing to worsened performance in safety profile.”

    In silicoAtrial fibrillation; excluding apixaban

    Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation

    International journal of cardiology

Cost-effectiveness relative to warfarin

upin silico1

1 study
  1. Novel oral anticoagulants improve cost-effectiveness relative to warfarin in silico (Atrial fibrillation; excluding dabigatran 110) (Incremental cost-effectiveness ratios USD 24,476–41,448; threshold USD 49,700).

    “Compared to warfarin, NOACs (except dabigatran 110) were associated with incremental cost-effectiveness ratios ranging from USD 24,476 to USD 41,448”

    In silicoAtrial fibrillation; excluding dabigatran 110Lifetime

    Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation

    International journal of cardiology

Bleeding

downin humans1

1 study
  1. Novel oral anticoagulants decrease bleeding in humans (compared with vitamin K antagonists).

    “a more favorable risk-benefit ratio mostly driven by the reduction of bleeding.”

    Reviewcompared with vitamin K antagonists

    New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients

    Zeitschrift fur Gerontologie und Geriatrie

More on Bleeding

What is novel oral anticoagulants linked with?

2

Studies link novel oral anticoagulants with 2 measures: mortality and cataract.

Mortality

downin humans2HR 0.6

2 studies
  1. Novel oral anticoagulants are associated with mortality in humans (End-stage renal failure and atrial fibrillation; compared with aspirin) (HR 0.60, 95% CI 0.44–0.80; P<0.001).

    “but lower all-cause death among NOAC users”

    HumansEnd-stage renal failure and atrial fibrillation; compared with aspirin

    Safety and Effectiveness of Antithrombotics in Patients with End-Stage Renal Failure and Atrial Fibrillation: A Population-Based Study with Competing Risk Analysis

    AHA Scientific Sessions 2026 abstract

  2. Novel oral anticoagulants are associated with mortality in humans (Patients with atrial fibrillation) (OR 0.7, 95% CI 0.46–0.91).

    “novel oral anticoagulants (OR 0.7, 95% CI 0.46 to 0.91) had protective effects from all-cause mortality.”

    HumansPatients with atrial fibrillation1 year

    The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study - A Prospective Cohort Study

    BMJ open

Cataract

downin humans1HR 0.89

1 study
  1. Novel oral anticoagulants are linked with a lower risk of cataract in humans (atrial fibrillation) (HR 0.89, 95% CI 0.87–0.92).

    “NOAC use was associated with a significantly lower risk of cataract compared with warfarin (HR 0.89, 95% CI 0.87–0.92).”

    Humansatrial fibrillationn = 252,520

    Newer blood thinners linked to lower cataract risk

    ESC Congress 2026 abstract

More on Cataract

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 14 papers in 12 months
ESC Congress 2026 Abstract

Newer blood thinners linked to lower cataract risk

An observational study of 252,520 adults with an irregular heartbeat linked newer blood thinners to lower cataract risk than warfarin (hazard ratio 0.89).An observational study of 252,520 adults with an irregular heartbeat linked newer blood thinners to lower cataract risk than warfarin (hazard ratio 0.89).

Cohort · 252,520 peopleCataract